PERFORMANCE OF THE ANTI-SCLEROSTIN ANTIBODY IN DENTISTRY

• Published in: Oral surgery, oral medicine, oral pathology and oral radiology Vol. 134; no. 3; p. e235
• Main Authors: De Lima Marinho Costa, Marina, Machado, Isadora Rios Rocha, Dantas, Rafaelly Pires, Da Silva, Bruna Santos, De Freitas Aleluia Costa, Diana Simões, Da Silva Paiva, Katiúcia Batista, De Aquino Xavier, Flávia Caló
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2022
• ISSN: 2212-4403; 2212-4411
• DOI: 10.1016/j.oooo.2022.01.756

Metabolic disorders can interfere with the balance of bone tissue that is maintained during the remodeling process. The use of anti-sclerostin antibody (Scl-Ab) is a promising treatment that has been suggested for this condition. The aim was to approach the vast and important role of the Scl-Ab in dentistry and highlight the importance of studies to obtain worldwide approval for the therapeutic agent, which can offer improved quality of life to several patients through bone mass gain. This article presents a narrative review approach using the keywords “dentistry” and “sclerostin” from the previous 5 years, including experimental and clinical studies that have evaluated the effect of Scl-Ab on the jaws. Scl-Ab has a potent anabolic effect on bone therapy, contributing both to increased bone formation and reduced resorption in patients who have certain deficiencies in bone metabolism. In dentistry, it can play an important role in several specialties because bone balance is fundamental to enable different treatments, such as surgery and maintenance of oral health. The regulation of sclerostin through the Scl-Ab is a current strategy in dentistry that aims at therapeutic bone regulation, with excellent results achieved so far that require validation for large-scale use.